In Vitro Diagnostics Market By Application (Infectious Diseases, Cardiology, Autoimmune Diseases, HIV/AIDS, Diabetes, Oncology/Cancer, Nephrology, Drug Testing, Others), By End User (Laboratories), By Product & Service (Instruments, Reagents & Kits, Data Management Software/Hardware, Services), By Technology (Hematology), Industry Size, Growth, Share And Forecast To 2022
Key Findings
The global in vitro diagnostics market is expected to grow at the CAGR of 6.4% during 2015-2022. The major factors driving the market are the rising rate of gastrointestinal diseases and the growth in geriatric population. According to census.gov, approx. 47.5 million people were aged 65 and above in the U.S. and are anticipated to reach around 60 million by the end of 2022. Rising aging population has led to the increasing demand for in vitro diagnostics in the U.S. The other key factors that are contributing significantly towards the growth of in vitro diagnostics market are rising awareness of personalized medicine as well as the increasing prevalence rate of diabetes. In China, the prevalence rate of diabetes among adults was 10.6% in 2015 and around 1,299,670 people died due to diabetes in 2015. Advancements in proteomics and genomics are anticipated to act as a key opportunity for the growth of the market. Although there are many factors driving the market, yet there are some challenges faced by the market such as reimbursement issues and stringent regulatory policies for the commercialization of medical devices.
Market Segment Insights
The market is majorly segmented on the basis of application, end user, product & service and technology. On the basis of application, the market is segmented into infectious diseases, cardiology, autoimmune diseases, HIV/AIDS, diabetes, oncology/cancer, nephrology, drug testing and other applications. The infectious diseases dominates the in vitro diagnostic market in application segment with 25% market share. The market can further be bifurcated on the basis of product & service including instruments, reagents & kits, data management software/hardware and services. Reagents account for 80% market share of the global in vitro diagnostic market in the product segment. The reason behind the growing reagents segment is the increasing number of diagnostic tests that are performed every year. On the basis of end user, the in vitro diagnostics market includes laboratories, academic institutes, patient self-testing, hospitals, point-of-care testing and other end users. It can further be segregated on the basis of technology such as hematology, microbiology, coagulation and hemostasis, clinical chemistry, molecular diagnostics, immunoassays and others. Immunoassays segment holds the largest market share with 27.8% of the global in vitro diagnostics market owing to its high specificity nature.
Regional Insights
Globally, the in vitro diagnostics market is segmented into North America, Europe, APAC, Middle East & Africa and Latin America. North America has the largest market share of in vitro diagnostics followed by Europe and Asia Pacific. In 2015, North America held approx.43% share of in vitro diagnostics market owing to the increasing prevalence of cancer and respiratory diseases in the region. According to National Cancer Institute, approx. 1,685,210 new cases of cancer are anticipated to be diagnosed in the U.S. amongst which 595,690 people are expected to lose their live due to this disease. In U.S., National expenditures for cancer care were nearly $125 billion in 2010 and are expected to reach $156 billion by 2020. This has led to the rising demand for in vitro diagnostics within the region. The various other factors that are boosting the demand for the in vitro diagnostics in North America are established distribution channels, presence of advanced technologies and the presence of key market players within the region such as Johnson and Johnson, Danaher Corporation, Abbott Laboratories Inc., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc. and Becton, Dickson & Company. Europe accounted for around 23% market share in the in vitro diagnostics market owing to supportive government initiatives, growing per capita health expenditure and growing clinical research activities concerning advanced diagnostics. Rising prevalence rate of cancer, pneumonia and tuberculosis are also anticipated to have a significant impact in the growth of European in vitro diagnostics market. Asia Pacific is expected to be the fastest growing region in the upcoming scenario due to the growing penetration of IVD technologies in China and India.
Competitive Insights
Some of the major market players are Abbott Laboratories Inc., Alere San Diego Inc., Becton Dickinson & Company, Bio-Rad Laboratories Inc., Danaher Corporation, Johnson & Johnson, Ortho Clinical Diagnostics Inc. etc. Acquisitions, new product development, joint ventures, mergers and expansions are the key strategies adopted by the market players to sustain in the market. In 2016, Bio-Rad Laboratories entered into an exclusive partnership with Illumina Inc. to develop the NGS (next generation sequencing) workflow for single cell analysis. The companies are expecting to launch the solution in late 2016 or in early 2017. In 2015, Abbott and Sekisui signed an agreement to provide coagulation testing solutions for laboratories at a global level. As per the agreement, Abbott will be the sole distributor of Sekisui CP 3000 coagulation instrument in the Europe, the U.S. and the various regions that recognize CE Mark. On the other hand, In Oct. 2015 Roche announced its HbA1c testing solution named the Cobas c 513 analyser for the diagnosis, risk identification and stringent monitoring of diabetes patients.
CHAP 1. METHODOLOGY & SCOPE 17
1.1. RESEARCH METHODOLOGY 17
1.2. RESEARCH SCOPE & ASSUMPTIONS 17
1.3. LIST OF DATA SOURCES 17
CHAP 2. EXECUTIVE SUMMARY 18
2.1. GLOBAL IN VITRO DIAGNOSTICS MARKET SUMMARY & KEY BUYING CRITERIA 18
2.2. GLOBAL IN VITRO DIAGNOSTICS MARKET OUTLOOK 18
2.3. MARKET SEGMENTATION ANALYSIS 18
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022 18
2.5. GLOBAL IN VITRO DIAGNOSTICS MARKET VALUE CHAIN ANALYSIS 18
2.6. VENDOR LANDSCAPE 18
CHAP 3. GLOBAL IN VITRO DIAGNOSTICS MARKET 19
3.1. MARKET DRIVER ANALYSIS 19
3.1.1. GROWTH IN GERIATRIC POPULATION 19
3.1.2. RISING AWARENESS OF PERSONALIZED MEDICINE 19
3.1.3. INCREASING PREVALENCE OF DIABETES 19
3.1.4. GROWING ADOPTION OF POINT-OF-CARE TESTING 19
3.1.5. RISING INCIDENT RATE OF SEXUALLY TRANSMITTED & GASTROINTESTINAL DISEASES 19
3.2. MARKET RESTRAINT ANALYSIS 19
3.2.1. REIMBURSEMENT ISSUES 19
3.2.2. ENFORCEMENT OF EXCISE DUTY BY THE U.S. GOVERNMENT 19
3.3. KEY OPPORTUNITIES 19
3.3.1. EMERGING ECONOMIES WITH INCREASED SPENDING CAPABILITIES 19
3.3.2. ADVANCEMENTS IN PROTEOMICS AND GENOMICS 19
3.4. CHALLENGES 19
3.4.1. STRINGENT REGULATORY POLICIES 19
CHAP 4. INDUSTRY ANALYSIS 20
4.1. GLOBAL IN VITRO DIAGNOSTICS MARKET– PORTER’S FIVE FORCE MODEL 20
4.2. GLOBAL IN VITRO DIAGNOSTICS MARKET– PESTEL ANALYSIS 20
4.3. GLOBAL IN VITRO DIAGNOSTICS MARKET– GAP ANALYSIS 20
CHAP 5. GLOBAL IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2012-2022 ($ BILLION) 21
5.1. GLOBAL IN VITRO DIAGNOSTICS MARKET BY INFECTIOUS DISEASES 2012-2022 ($ BILLION) 21
5.2. GLOBAL IN VITRO DIAGNOSTICS MARKET BY CARDIOLOGY 2012-2022 ($ BILLION) 21
5.3. GLOBAL IN VITRO DIAGNOSTICS MARKET BY AUTOIMMUNE DISEASES 2012-2022 ($ BILLION) 21
5.4. GLOBAL IN VITRO DIAGNOSTICS MARKET BY HIV/AIDS 2012-2022 ($ BILLION) 21
5.5. GLOBAL IN VITRO DIAGNOSTICS MARKET BY DIABETES 2012-2022 ($ BILLION) 21
5.6. GLOBAL IN VITRO DIAGNOSTICS MARKET BY ONCOLOGY/CANCER 2012-2022 ($ BILLION) 21
5.7. GLOBAL IN VITRO DIAGNOSTICS MARKET BY NEPHROLOGY 2012-2022 ($ BILLION) 21
5.8. GLOBAL IN VITRO DIAGNOSTICS MARKET BY DRUG TESTING 2012-2022 ($ BILLION) 21
5.9. GLOBAL IN VITRO DIAGNOSTICS MARKET BY OTHER APPLICATIONS 2012-2022 ($ BILLION) 21
CHAP 6. GLOBAL IN VITRO DIAGNOSTICS MARKET BY END USER 2012-2022 ($ BILLION) 22
6.1. GLOBAL IN VITRO DIAGNOSTICS MARKET BY LABORATORIES 2012-2022 ($ BILLION) 22
CHAP 7. GLOBAL IN VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICE ($ BILLION) 23
7.1. GLOBAL IN VITRO DIAGNOSTICS MARKET BY INSTRUMENTS 2012-2022 ($ BILLION) 23
7.2. GLOBAL IN VITRO DIAGNOSTICS MARKET BY REAGENTS & KITS 2012-2022 ($ BILLION) 23
7.3. GLOBAL IN VITRO DIAGNOSTICS MARKET BY DATA MANAGEMENT SOFTWARE/HARDWARE 2012-2022 ($ BILLION) 23
7.4. GLOBAL IN VITRO DIAGNOSTICS MARKET BY SERVICES 2012-2022 ($ BILLION) 23
CHAP 8. GLOBAL IN VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2012-2022 ($ BILLION) 24
8.1. GLOBAL IN VITRO DIAGNOSTICS MARKET BY HEMATOLOGY 2012-2022 ($ BILLION) 25
8.1.1. GLOBAL ELECTROLYTE PANELS MARKET 2012-2022 ($ BILLION) 25
8.1.2. GLOBAL LIPID PROFILES MARKET 2012-2022 ($ BILLION) 25
8.1.3. GLOBAL THYROID FUNCTION PANELS MARKET 2012-2022 ($ BILLION) 25
8.1.4. GLOBAL BASIC METABOLIC PANEL MARKET 2012-2022 ($ BILLION) 25
8.1.5. GLOBAL LIVER PANELS MARKET 2012-2022 ($ BILLION) 25
8.1.6. GLOBAL RENAL PROFILES MARKET 2012-2022 ($ BILLION) 25
8.1.7. GLOBAL SPECIALTY CHEMICAL TESTS MARKET 2012-2022 ($ BILLION) 25
8.1.8. GLOBAL POLYMERASE CHAIN REACTION (PCR)MARKET 2012-2022 ($ BILLION) 25
8.1.9. GLOBAL MICROARRAYS MARKET 2012-2022 ($ BILLION) 25
8.1.10. GLOBAL DNA SEQUENCING & NEXT-GENERATION SEQUENCING MARKET 2012-2022 ($ BILLION) 26
8.1.11. GLOBAL ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) MARKET 2012-2022 ($ BILLION) 26
8.1.11. GLOBAL HYBRIDIZATION MARKET 2012-2022 ($ BILLION) 26
8.1.12. GLOBAL OTHERS MARKET 2012-2022 ($ BILLION) 26
8.1.13. GLOBAL RADIOIMMUNOASSAYS (RIA)MARKET 2012-2022 ($ BILLION) 26
8.1.14. GLOBAL WESTERN BLOT MARKET 2012-2022 ($ BILLION) 26
8.1.15. GLOBAL RAPID TESTS MARKET 2012-2022 ($ BILLION) 26
8.1.16. GLOBAL ELISPOT MARKET 2012-2022 ($ BILLION) 26
8.1.17. GLOBAL ELISA MARKET 2012-2022 ($ BILLION) 26
8.1.18. GLOBAL FLUORESCENCE IMMUNOASSAYS (FIA) MARKET 2012-2022 ($ BILLION) 26
8.1.19. GLOBAL CHEMILUMINESCENCE IMMUNOASSAYS (CLIAS) MARKET 2012-2022 ($ BILLION) 26
8.1.20. GLOBAL COLORIMETRIC IMMUNOASSAYS (CI) MARKET 2012-2022 ($ BILLION) 26
CHAP 9. GLOBAL IN VITRO DIAGNOSTICS MARKET REGIONAL OUTLOOK 2012-2022 ($ BILLION) 27
9.1. GLOBAL IN VITRO DIAGNOSTICS MARKET BY REGION 2012-2022 ($ BILLION) 27
9.2. NORTH AMERICA 27
9.2.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
9.2.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 27
9.2.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 27
9.2.3.1. U.S. 27
9.2.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
9.2.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 27
9.2.3.2. CANADA 27
9.2.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 28
9.2.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 28
9.3. EUROPE 28
9.3.1. EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 28
9.3.2. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 28
9.3.3. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 28
9.3.3.1. GERMANY 28
9.3.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 28
9.3.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 28
9.3.3.2. UK 28
9.3.3.2.1. UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 28
9.3.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 28
9.3.3.3. FRANCE 28
9.3.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 28
9.3.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 28
9.3.3.4. SPAIN 28
9.3.3.4.1. SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
9.3.3.4.2. SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 29
9.3.3.5. REST OF EUROPE 29
9.3.3.5.1. RUSSIA MARKET ESTIMATES AND FORECAST 2012-2022($ BILLION) 29
9.3.3.5.2. RUSSIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 29
9.3.3.5.3. OTHERS MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
9.3.3.5.4. OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($ BILLION) 29
9.4. ASIA PACIFIC 29
9.4.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
9.4.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 29
9.4.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 29
9.4.3.1. CHINA 29
9.4.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
9.4.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 29
9.4.3.2. INDIA 29
9.4.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
9.4.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 30
9.4.3.3. JAPAN 30
9.4.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
9.4.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 30
9.4.3.4. OTHERS 30
9.4.3.4.1. OTHER MARKET ESTIMATES AND FORECASTS 2012-2022 ($ BILLION) 30
9.4.3.4.2. OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 30
9.5. MIDDLE EAST & AFRICA 30
9.5.1. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
9.5.2. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 30
9.6. LATIN AMERICA 30
9.6.1. LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
9.6.2. LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 30
9.6.2.1. BRAZIL 30
9.6.2.1.1. BRAZIL MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
9.6.2.1.2. BRAZIL MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 31
CHAP 10. COMPETITIVE LANDSCAPE 32
10.1. ABBOTT LABORATORIES, INC. 33
10.1.1. COMPANY OVERVIEW 33
10.1.2. FINANCIAL PERFORMANCE 33
10.1.3. PRODUCT BENCHMARKING 33
10.1.4. STRATEGIC INITIATIVES 33
10.2. ALERE SAN DIEGO INC. 33
10.2.1. COMPANY OVERVIEW 33
10.2.2. FINANCIAL PERFORMANCE 33
10.2.3. PRODUCT BENCHMARKING 33
10.2.4. STRATEGIC INITIATIVES 33
10.3. BECTON, DICKINSON AND COMPANY 33
10.3.1. COMPANY OVERVIEW 33
10.3.2. FINANCIAL PERFORMANCE 33
10.3.3. PRODUCT BENCHMARKING 33
10.3.4. STRATEGIC INITIATIVES 33
10.4. BIOMÉRIEUX 33
10.4.1. COMPANY OVERVIEW 33
10.4.2. FINANCIAL PERFORMANCE 33
10.4.3. PRODUCT BENCHMARKING 33
10.4.4. STRATEGIC INITIATIVES 33
10.5. BIO-RAD LABORATORIES, INC. 33
10.5.1. COMPANY OVERVIEW 33
10.5.2. FINANCIAL PERFORMANCE 33
10.5.3. PRODUCT BENCHMARKING 33
10.5.4. STRATEGIC INITIATIVES 33
10.6. DANAHER CORPORATION 33
10.6.1. COMPANY OVERVIEW 34
10.6.2. FINANCIAL PERFORMANCE 34
10.6.3. PRODUCT BENCHMARKING 34
10.6.4. STRATEGIC INITIATIVES 34
10.7. ELITECH GROUP 34
10.7.1. COMPANY OVERVIEW 34
10.7.2. FINANCIAL PERFORMANCE 34
10.7.3. PRODUCT BENCHMARKING 34
10.7.4. STRATEGIC INITIATIVES 34
10.8. JOHNSON AND JOHNSON 34
10.8.1. COMPANY OVERVIEW 34
10.8.2. FINANCIAL PERFORMANCE 34
10.8.3. PRODUCT BENCHMARKING 34
10.8.4. STRATEGIC INITIATIVES 34
10.9. ORTHO CLINICAL DIAGNOSTICS, INC. 34
10.9.1. COMPANY OVERVIEW 34
10.9.2. FINANCIAL PERFORMANCE 34
10.9.3. PRODUCT BENCHMARKING 34
10.9.4. STRATEGIC INITIATIVES 34
10.10. ROCHE DIAGNOSTICS 34
10.10.1. COMPANY OVERVIEW 34
10.10.2. FINANCIAL PERFORMANCE 34
10.10.3. PRODUCT BENCHMARKING 34
10.10.4. STRATEGIC INITIATIVES 34
10.11. SIEMENS HEALTHCARE 34
10.11.1. COMPANY OVERVIEW 34
10.11.2. FINANCIAL PERFORMANCE 35
10.11.3. PRODUCT BENCHMARKING 35
10.11.4. STRATEGIC INITIATIVES 35
10.12. SYSMEX CORPORATION 35
10.12.1. COMPANY OVERVIEW 35
10.12.2. FINANCIAL PERFORMANCE 35
10.12.3. PRODUCT BENCHMARKING 35
10.12.4. STRATEGIC INITIATIVES 35
10.13. THERMO FISHER SCIENTIFIC INC. 35
10.13.1. COMPANY OVERVIEW 35
10.13.2. FINANCIAL PERFORMANCE 35
10.13.3. PRODUCT BENCHMARKING 35
10.13.4. STRATEGIC INITIATIVES 35
10.14. TRANSASIA BIO-MEDICALS 35
10.14.1. COMPANY OVERVIEW 35
10.14.2. FINANCIAL PERFORMANCE 35
10.14.3. PRODUCT BENCHMARKING 35
10.14.4. STRATEGIC INITIATIVES 35
10.15. WERFEN GROUP 35
10.15.1. COMPANY OVERVIEW 35
10.15.2. FINANCIAL PERFORMANCE 35
10.15.3. PRODUCT BENCHMARKING 35
10.15.4. STRATEGIC INITIATIVES 35
TABLE 1 GLOBAL IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 2 GLOBAL IN VITRO DIAGNOSTICS MARKET BY INFECTIOUS DISEASES 2012-2022 ($ BILLION) 34
TABLE 3 GLOBAL IN VITRO DIAGNOSTICS MARKET BY CARDIOLOGY 2012-2022 ($ BILLION) 34
TABLE 4 GLOBAL IN VITRO DIAGNOSTICS MARKET BY AUTOIMMUNE DISEASES 2012-2022 ($ BILLION) 34
TABLE 5 GLOBAL IN VITRO DIAGNOSTICS MARKET BY HIV/AIDS 2012-2022 ($ BILLION) 34
TABLE 6 GLOBAL IN VITRO DIAGNOSTICS MARKET BY DIABETES 2012-2022 ($ BILLION) 34
TABLE 7 GLOBAL IN VITRO DIAGNOSTICS MARKET BY ONCOLOGY/CANCER 2012-2022 ($ BILLION) 34
TABLE 8 GLOBAL IN VITRO DIAGNOSTICS MARKET BY NEPHROLOGY 2012-2022 ($ BILLION) 34
TABLE 9 GLOBAL IN VITRO DIAGNOSTICS MARKET BY DRUG TESTING 2012-2022 ($ BILLION) 34
TABLE 10 GLOBAL IN VITRO DIAGNOSTICS MARKET BY OTHER APPLICATIONS 2012-2022 ($ BILLION) 34
TABLE 11 GLOBAL IN VITRO DIAGNOSTICS MARKET BY END USER 2012-2022 ($ BILLION) 34
TABLE 12 GLOBAL IN VITRO DIAGNOSTICS MARKET BY LABORATORIES 2012-2022 ($ BILLION) 35
TABLE 13 GLOBAL IN VITRO DIAGNOSTICS MARKET BY ACADEMIC INSTITUTES 2012-2022 ($ BILLION) 35
TABLE 14 GLOBAL IN VITRO DIAGNOSTICS MARKET BY PATIENT SELF-TESTING 2012-2022 ($ BILLION) 35
TABLE 15 GLOBAL IN VITRO DIAGNOSTICS MARKET BY HOSPITALS 2012-2022 ($ BILLION) 35
TABLE 16 GLOBAL IN VITRO DIAGNOSTICS MARKET BY POINT-OF-CARE TESTING 2012-2022 ($ BILLION) 35
TABLE 17 GLOBAL IN VITRO DIAGNOSTICS MARKET BY OTHERS 2012-2022 ($ BILLION) 35
TABLE 18 GLOBAL IN VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICE ($ BILLION) 35
TABLE 19 GLOBAL IN VITRO DIAGNOSTICS MARKET BY INSTRUMENTS 2012-2022 ($ BILLION) 35
TABLE 20 GLOBAL IN VITRO DIAGNOSTICS MARKET BY REAGENTS & KITS 2012-2022 ($ BILLION) 35
TABLE 21 GLOBAL IN VITRO DIAGNOSTICS MARKET BY DATA MANAGEMENT SOFTWARE/HARDWARE 2012-2022 ($ BILLION) 35
TABLE 22 GLOBAL IN VITRO DIAGNOSTICS MARKET BY SERVICES 2012-2022 ($ BILLION) 35
TABLE 23 GLOBAL IN VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2012-2022 ($ BILLION) 35
TABLE 24 GLOBAL IN VITRO DIAGNOSTICS MARKET BY HEMATOLOGY 2012-2022 ($ BILLION) 35
TABLE 25 GLOBAL IN VITRO DIAGNOSTICS MARKET BY MICROBIOLOGY 2012-2022 ($ BILLION) 35
TABLE 26 GLOBAL IN VITRO DIAGNOSTICS MARKET BY COAGULATION AND HEMOSTASIS 2012-2022 ($ BILLION) 35
TABLE 27 GLOBAL IN VITRO DIAGNOSTICS MARKET BY CLINICAL CHEMISTRY 2012-2022 ($ BILLION) 35
TABLE 28 GLOBAL ELECTROLYTE PANELS MARKET 2012-2022 ($ BILLION) 36
TABLE 29 GLOBAL LIPID PROFILES MARKET 2012-2022 ($ BILLION) 36
TABLE 30 GLOBAL THYROID FUNCTION PANELS MARKET 2012-2022 ($ BILLION) 36
TABLE 31 GLOBAL BASIC METABOLIC PANEL MARKET 2012-2022 ($ BILLION) 36
TABLE 32 GLOBAL LIVER PANELS MARKET 2012-2022 ($ BILLION) 36
TABLE 33 GLOBAL RENAL PROFILES MARKET 2012-2022 ($ BILLION) 36
TABLE 34 GLOBAL SPECIALTY CHEMICAL TESTS MARKET 2012-2022 ($ BILLION) 36
TABLE 35 GLOBAL IN VITRO DIAGNOSTICS MARKET BY MOLECULAR DIAGNOSTICS 2012-2022 ($ BILLION) 36
TABLE 36 GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET 2012-2022 ($ BILLION) 36
TABLE 37 GLOBAL MICROARRAYS MARKET 2012-2022 ($ BILLION) 36
TABLE 38 GLOBAL DNA SEQUENCING & NEXT-GENERATION SEQUENCING MARKET 2012-2022 ($ BILLION) 36
TABLE 39 GLOBAL ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) MARKET 2012-2022 ($ BILLION) 36
TABLE 40 GLOBAL HYBRIDIZATION MARKET 2012-2022 ($ BILLION) 36
TABLE 41 GLOBAL OTHERS MARKET 2012-2022 ($ BILLION) 36
TABLE 42 GLOBAL IN VITRO DIAGNOSTICS MARKET BY IMMUNOASSAYS 2012-2022 ($ BILLION) 36
TABLE 43 GLOBAL RADIOIMMUNOASSAYS (RIA) MARKET 2012-2022 ($ BILLION) 36
TABLE 44 GLOBAL WESTERN BLOT MARKET 2012-2022 ($ BILLION) 36
TABLE 45 GLOBAL RAPID TESTS MARKET 2012-2022 ($ BILLION) 36
TABLE 46 GLOBAL ELISPOT MARKET 2012-2022 ($ BILLION) 37
TABLE 47 GLOBAL ELISA MARKET 2012-2022 ($ BILLION) 37
TABLE 48 GLOBAL FLUORESCENCE IMMUNOASSAYS (FIA) MARKET 2012-2022 ($ BILLION) 37
TABLE 49 GLOBAL CHEMILUMINESCENCE IMMUNOASSAYS (CLIAS) MARKET 2012-2022 ($ BILLION) 37
TABLE 50 GLOBAL COLORIMETRIC IMMUNOASSAYS (CI) MARKET 2012-2022 ($ BILLION) 37
TABLE 51 GLOBAL IN VITRO DIAGNOSTICS MARKET BY OTHERS 2012-2022 ($ BILLION) 37
TABLE 52 GLOBAL IN VITRO DIAGNOSTICS MARKET REGIONAL OUTLOOK 2012-2022 ($ BILLION) 37
TABLE 53 GLOBAL IN VITRO DIAGNOSTICS MARKET BY REGION 2012-2022 ($ BILLION) 37
TABLE 54 NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37
TABLE 55 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 37
TABLE 56 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 37
TABLE 57 U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37
TABLE 58 U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 37
TABLE 59 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37
TABLE 60 CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 37
TABLE 61 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37
TABLE 62 EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 37
TABLE 63 EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 38
TABLE 64 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 38
TABLE 65 GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 38
TABLE 66 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 38
TABLE 67 UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 38
TABLE 68 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 38
TABLE 69 FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 38
TABLE 70 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 38
TABLE 71 SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 38
TABLE 72 RUSSIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 38
TABLE 73 RUSSIA MARKET ESTIMATES AND FORECAST BY APPLICATIONN 2012-2022 ($ BILLION) 38
TABLE 74 OTHERS MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 38
TABLE 75 OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 38
TABLE 76 ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 38
TABLE 77 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 38
TABLE 78 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 38
TABLE 79 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 39
TABLE 80 CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 39
TABLE 81 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 39
TABLE 82 INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 39
TABLE 83 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 39
TABLE 84 JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 39
TABLE 85 OTHER MARKET ESTIMATES AND FORECASTS 2012-2022 ($ BILLION) 39
TABLE 86 OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 39
TABLE 87 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 39
TABLE 88 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 39
TABLE 89 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 39
TABLE 90 LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 39
TABLE 91 BRAZIL MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 39
TABLE 92 BRAZIL MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 39
FIGURE 1 MARKET SHARE BY REGIONS 39
FIGURE 2 UNITED STATES MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 40
FIGURE 3 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 40
FIGURE 4 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 40
FIGURE 5 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 40
FIGURE 6 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 40
FIGURE 7 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 40
FIGURE 8 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 40
FIGURE 9 REST OF EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 40
FIGURE 10 APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 40
FIGURE 11 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 40
FIGURE 12 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 40
FIGURE 13 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 40
FIGURE 14 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 40
FIGURE 15 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 40
FIGURE 16 BRAZIL MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 40
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)